biohaven: "rimegepant pivotal phase 3 trial results -- conference call.". print. december 2010  (15)..

the news highlighted another factor in the chinese threat: regardless of the different regulatory framework, many researchers think the data they report is valid..

the publication�s purpose is to be a "force for good and a platform for much needed change and to generate critical debate"..

mainstream reporters and editors and publishers are well aware that telling the truth and continuing to pound on it would undermine a basic institution of society...